GLP-1orforglipronglp-1type-2-diabetescardiovascular-safetylancet

Lancet paper addresses cardiovascular safety of orforglipron in type 2 diabetes

The oral small-molecule GLP-1 receptor agonist is assessed on cardiovascular safety, the standard regulatory requirement for new type 2 diabetes therapies.

By Maren Holt · Senior Reporter, GLP-1

Oct 16 07:00 ETSource: Lancet (London, England)

The wire

01The Lancet publishes work by Kang, Nauck and colleagues establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.
02Cardiovascular safety is a gating requirement for diabetes drug approval, and orforglipron is the furthest along oral non-peptide GLP-1 agonist.
03Detailed endpoints, event counts and follow-up duration are not available from the title alone; clinicians should read the full report before drawing conclusions.

From the source

Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes
Lancet (London, England) · 2026 Oct 17 · Kang YM, Nauck MA et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42880294/